SecBot SecBot
8-K ·Filed Nov 10, 2026

LABT

Lakewood-Amedex Biotherapeutics Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6d 10h ago SEC0001213900-26-118127
8-K material event: Items 1.01
Actionable Insight • Neutral

The redemption removes a dilutive overhang but consumed most of the company's cash. Monitor subsequent filings for cash runway updates and potential need for new financing to fund operations.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.3950
T+0 close · Nov 10, 2026 · via day close
Latest settled
−9.06%
T+1 · $0.3592
Vs SPY
−8.71%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $0.3950entry
  2. T+1 · 5d ago −9.06%α −8.71% · $0.3592
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lakewood-Amedex redeemed all 127,097 outstanding shares of Series C Convertible Preferred Stock for $1,270,970 in cash from available funds, eliminating the potential for future dilution from conversion and leaving no preferred shares or outstanding debt. The transaction simplifies the capital structure and removes financing restrictions, but consumed a material portion of the company's cash on hand given its $1M market cap.

Key Financial Metrics

Deal Value
$1.3M

Key Facts

  • Redeemed 127,097 Series C Preferred shares for $1,270,970 in cash ($10.00 per share face value)
  • Redemption closed on November 4, 2026; no Series C shares remain outstanding
  • Company now has no preferred stock outstanding and no outstanding indebtedness for borrowed money
  • Redemption eliminates potential future dilution from conversion of Series C Preferred Stock
  • Cash used for redemption was from available funds (cash on hand)
  • Company has a market cap of approximately $1M

Financial Impact

Cash outflow of $1,270,970, which is approximately 127% of the company's $1M market cap, representing a significant use of available cash.

cashdilutioncapital structure

Risk Factors

  • Cash used for redemption may reduce liquidity and cash runway for clinical development
  • Company may need to raise additional capital, potentially causing dilution to common shareholders
  • No revenue-generating products; clinical-stage biotech with ongoing cash burn

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-118127
Document: ea031157601ex99-1.htm0001213900-26-118127
Document: 0001213900-26-118127-index-headers.html0001213900-26-118127
Document: 0001213900-26-118127-index.html0001213900-26-118127
Document: 0001213900-26-118127.txt0001213900-26-118127

Track record

10 reports on LABT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +88.01% at T+60 after the May 14, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bearish 7/10 Entry $0.2241 Now $0.2200 +1.83% settles Dec 16
  2. Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $0.3950 Now $0.2200 −44.30% settles Dec 10
  3. Sep 25, 20267w ago EFFECT Bullish 6/10 Entry $1.67 to $0.3100 Now $0.2200 −86.83% ▼ −81.44% −79.96% vs SPY
  4. Sep 18, 20268w ago S-1 Bearish 5/10 Entry $2.05 to $0.5834 Now $0.2200 +89.27% ▲ +71.54% +70.63% vs SPY
  5. Jun 17, 202621w ago 8-K Neutral 3/10 Entry $0.6022 to $0.1890 Now $0.2200 −63.47% ▼ −68.62% −68.93% vs SPY
  6. May 14, 202626w ago EFFECT Bearish 5/10 Entry $19.60 to $7.70 Now $0.2200 +98.88% ▲ +60.71% +59.86% vs SPY
  7. May 6, 202627w ago 3 Neutral 2/10 Entry $33.00 to $6.70 Now $0.2200 −99.33% ▼ −79.70% −80.51% vs SPY
  8. Apr 20, 202630w ago EFFECT Neutral 6/10 No price data
  9. Apr 1, 202632w ago S-1/A Bearish 5/10 No price data
  10. Mar 11, 202635w ago S-1/A Neutral 4/10 No price data
Showing 10 of 10

US Market Status

Market Closed · Opens in 5h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026